GlaxoSmithKline wanted a dynamic-duo designation for its two new melanoma drugs, Tafinlar and Mekinist. And now, the FDA has come through. The agency approved the two targeted treatments for use in tandem, in patients with particular genetic mutations.
Melbourne, Victoria, Australia.